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InﬂammationVarious stem cell-based approaches for cardiac repair have achieved encouraging results in animal experiments,
often leading to their rapid proceeding to clinical testing. However, freewheeling evolutionary developments of
the stem cell theory might lead to dystopian scenarios where heterogeneous sources of therapeutic cells could
promote mixed clinical outcomes in un-stratiﬁed patient populations. This review focuses on the lessons that
should be learnt from the ﬁrst generation of stem cell-based strategies and emphasizes the absolute requirement
to better understand the basic mechanisms of stem cell biology and cardiogenesis. Wewill also discuss about the
unexpected “big bang” in the stem cell theory, “blasting” the therapeutic cells to their unchallenged ability to re-
lease paracrine factors such as extracellular membrane vesicles. Paradoxically, the natural evolution of the stem
cell theory for cardiac regeneration may end with the development of cell-free strategies with multiple cellular
targets including cardiomyocytes but also other inﬁltrating or resident cardiac cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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major problem of global health causing around 5% of the acute hospital
admissions and accounting for around 10% of hospitalized patients in
Europe and the United States. Importantly, the number of patients
with HF is steadily increasing, as a consequence of an aging population, Paris Cardiovascular research
ris, France.
J.-S. Silvestre),
. This is an open access article underand/or enlarging prevalence of cardiovascular risk factors such as diabe-
tes (Gilbert and Krum, 2015) and improved survival rates after acute
myocardial infarction (MI) putting a greater number of patients at risk
of developing a late left ventricular dysfunction. Nevertheless, long-
term survival has improved with recentmedical therapies aiming at re-
ducing cardiac overload and neurohumoral activation, aswell asminer-
alocorticoid deregulation. Signiﬁcant advances have also been achieved
through surgical revascularization strategies including percutaneous
coronary angioplasty and coronary artery bypass grafting. Current strat-
egies for treating end-stage HF are based on replacing or supporting the
failing heart by cardiac transplantation or left ventricular assist devices.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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40% of them perish or are readmitted to hospital within the ﬁrst year.
The poor prognosis of symptomatic HF is likely associated with the lim-
ited long-term efﬁcacy of conventional therapeutic strategies on the un-
derlying ongoing loss of cardiomyocytes, which is followed by the
deleterious formation of a ﬁbrotic scar in the failing heart.
Over the last decade, the classical paradigm that thehumanheart is a
post-mitotic and terminally developed organwith no cell renewal capa-
bility has been underminedwith the demonstration that cardiomyocyte
turnover can occur in adult mammals, including humans (Sahara et al.,
2015; Bergmann et al., 2009; Bergmann et al., 2015). However, such in-
herent capability of humans to regenerate myocardium with aging or
after injury in adulthood is entirely insufﬁcient to fully compensate for
the loss of function associated with these conditions. Such statement
confronts the scientiﬁc community with a unique and exciting chal-
lenge: canwe enhance the regenerative capacity of cardiac tissue to ab-
rogate adverse ventricular remodeling? Consistent with this, multiple
different approaches have been developed to promote cardiomyocyte re-
generation/proliferation in human injured hearts, including transplanta-
tion of autologous non-cardiac/cardiac somatic stem cells, injection of in
vitro-derived cardiomyocytes, direct reprogramming of cardiac ﬁbro-
blasts into cardiomyocytes in vivo, stimulation of dedifferentiation/
proliferation of resident cardiomyocytes, and activation of endogenous
cardiac progenitor cell populations. These therapeutic strategies, classi-
ﬁed as either cell-based or cell-free, are currently being investigated for
their cardiac repair potential and clinical application.
In particular, various cell-based approaches for cardiac repair have
achieved encouraging results in animal experiments, often leading to
their rapid proceeding to clinical testing. Although a multitude of clini-
cal trials have been performed to date, their results remain ambiguous
and no single-cell-based therapy for heart disease has been conclusively
proven effective so far (Behfar et al., 2014). As a prototypic example of
such controversy, two recent meta-analysis of cell-based therapy one
in chronic HF (Fisher et al., 2015) and one in patients with acute MI
(Gyongyosi et al., 2015) result in entirely different conclusions. In the
meta-analysis of 31 randomized cell therapy trials in HFwhich included
1521 patients, exercise capacity, left ventricular ejection fraction and
quality of life are improved in the treated patients (Fisher et al., 2015).
In contrast, a second meta-analysis based on individual patient data re-
veals that cell therapy does not impact cardiac function and remodeling
as well as the clinical outcome in patients with acute MI (Gyongyosi
et al., 2015).
Such controversies prompt us to suggest thatwe need to step back in
the natural evolution of the stem cell theory for therapeutic use and go
“back to the trees” as claimed by the anti-progressive character from the
famous novel of Roy Lewis (The Evolution Man). In other words, we
need to go back to the root of stem cell biology and the concept of regen-
erative medicine. A clear understanding of stem cell biology and HF eti-
ologymay help researchers and clinicians in the ﬁeld to provide deﬁnite
evidences for stem cell efﬁcacy in patients.
1. The Quest for the Ideal Source of Stem Cells With Regenerative or
Cardiogenic Potential
There are a myriad of unresolved questions related to cell handling
and preparation, repair ability of the failing heart (inﬂammatory status,
timing of injection, endogenous cardiogenic and angiogenic potential),
mode of cell delivery, clinical endpoints as well as methodologies used
to assess those endpoints and this list is not exclusive.
Above all, there is no consensus on the basic question: which cell
type to transplant, to improve efﬁcacy and safety? The majority of trials
used adult stem cells and mainly applied total bone marrow-derived
mononuclear cells, bone marrow-derived marker selected cells or
granulocyte-colony stimulating factor mobilized mononuclear cells
(Silvestre et al., 2013). However, adult stem cells showa restrictive plas-
ticity andmore importantly most of the cardiovascular risk factors suchas hypertension, diabetes, aging and active smoking have been shown
to reduce the therapeutic potential of transplanted bone marrow-
derived cells (Govaert et al., 2009; Ayala-Lugo et al., 2011; Ebrahimian
et al., 2006; You et al., 2008; Roncalli et al., 2011). In addition, operating
procedures to isolate these bonemarrow derived cells are not standard-
ized. Some of the trials used Ficoll-gradient, sedimentation or automat-
ed systems to isolate bone marrow cells. This may lead to profound
heterogeneity in the therapeutic efﬁciency since cell isolation protocols
have amajor impact on the functional activity ofmedullary cells (Seeger
et al., 2007). Consistent with this, bone marrow-derived cells stored in
non-buffered saline supplemented with heparin, display reduction in
their homing and functional activity even in animal models (Seeger
et al., 2012). Other trials applied bone marrow-derived mesenchymal
stem cells (Mathiasen et al., 2015;Hare et al., 2012; Heldman et al.,
2014), bonemarrow-derivedmesenchymal stem cells exposed to a car-
diogenic cocktail (Bartunek et al., 2013), skeletal myoblast-derived cells
(Menasche et al., 2008) or adipose tissue-derived mesenchymal stem
cells (ADSCs) (Perin et al., 2014; Houtgraaf et al., 2012). This latter
source of therapeutic cells is also a good illustration of anticipated het-
erogeneity in future clinical trials. Adipose tissue-derived stem cells
can be obtained from subcutaneous adipose tissues with the use of col-
lagenase digestion. However, freshly isolated cells, also deﬁned as the
stromavascular fraction (SVF), are known to be heterogeneous and con-
tain hematopoietic cells and should be distinguished from ADSCs ob-
tained after culture on plastic dishes. ADSCs, but not SVF, show a
therapeutic effect in ischemic tissue in bothmice and humanswith crit-
ical limb ischemia (Planat-Benard et al., 2004; Lee et al., 2012b). In addi-
tion the source of fat has been shown to dictate human ADSCs
reparative activity (Naftali-Shani et al., 2013).
Although, there are many examples of therapies that appeared
promising in animal studies, but which failed in the clinics, all lessons
from experimental works should at least be considered before taking
any deﬁnitive conclusions on this ﬁrst generation of cell therapy. Very
few studies attempt to rigorously compare the therapeutic potential of
different sources of stem cells. Nevertheless, the best cardiac outcomes
seem to be achieved by therapeutic cells obligated to a cardiomyocyte
lineage. Hence, in experimental studies which have compared different
cell types, cardiac-committed cells (c-kit+ or Sca-1+ cardiac stem cells,
cardiospheres, induced pluripotent stem cell-derived cardiomyocytes)
display greater therapeutic effects compared to those of cells not com-
mitted to a cardiac lineage such as bone marrow mononuclear cells,
mesenchymal stem cells or skeletal myoblasts (Rossini et al., 2011;
Oskouei et al., 2012; Li et al., 2012; Zheng et al., 2013; Citro et al.,
2014). Of note, the superiority of cardiac-committed cells could be evi-
dencedon thebasis of various endpoints such as better engraftment, re-
duced extent of infarction and ﬁbrosis, increase in angiogenesis,
improvement of cardiac function and even mitigation of ventricular ar-
rhythmias. In linewith these observations, cardiac-committed cell ther-
apies are being tested in the clinics using cardiosphere-derived cells
obtained from a right ventricular biopsy (Makkar et al., 2012), c-kit+
cardiac progenitor cells grown from an intra-operatively harvested
right appendage biopsy (Chugh et al., 2012; Bolli et al., 2013) and em-
bryonic stem cell-derived cardiac progenitors (Menasche et al., 2015)
which are currently tested in a pilot safety trial. Of interest, in a mouse
model of acute MI, cardiosphere-derived cells isolated from HF patients
led to the greatest therapeutic beneﬁt with the highest left ventricular
ejection fraction when compared to cells isolated from non-failing do-
nors, suggesting that the overall efﬁcacy of this stem cell approach is
not necessarily dampened by the extent of the underlying left ventricu-
lar dysfunction (Cheng et al., 2014). Human-induced pluripotent stem
cells are another potentially unlimited source for generation of
cardiomyocytes (iPSC-CMs). However, current protocols for iPSC-CM
derivation face several challenges, including variability in somatic cell
sources and inconsistencies in cardiac differentiation efﬁciency. In addi-
tion, the overall therapeutic effect of the pluripotent stem cell-derived
progeny may also depend on the degree of maturity of the stem/
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scription factors early in the differentiation process (Sanchez-Freire
et al., 2014) whereas, unexpectedly, the extent of viability may not be
as critical as usually thought. Namely, implantation, in a chronic infarc-
tion model, of engineered heart muscle constructed from human em-
bryonic stem cell-derived cardiomyocytes led to high engraftment
rates, long-term survival, and progressive maturation of human
cardiomyocytes.With similar (and better than controls) functional out-
comes regardless of the cells were viable or irradiated (i.e., nonviable),
(Riegler, et al. 2015), which indirectly argues in favor of a paracrine
mechanism of action (see below). Hence, standardized protocols to
produce human stem cell-derived or directly reprogrammed
cardiomyocytes or cardiac progenitors exhibiting “appropriate”matu-
ration levels and engraftment are lacking.
More generally, our incomplete understanding of how the
human heart develops and can regenerate, and of which intrinsic
factor(s) account for the ultimate differences in regenerative capacities
between lower vertebrate or neonatal mammalian hearts and adult
mammalian hearts reduces the probability of success in our quest for
the ideal source of stem cells for cardiac repair. For instance, cardiac pro-
genitor cells are multipotent and give rise to cardiac endothelium,
smooth muscle, and cardiomyocytes. A recent and very elegant study
characterizes the cardiomyoblast intermediate that is committed to
the cardiomyocyte fate. Such cardiomyoblasts express Hopx, which
functions to coordinate local Bmp signals to inhibit the Wnt pathway,
thus promoting cardiomyogenesis. The identiﬁcation of this committed
cardiomyoblast that retains a proliferative potential might be leveraged
to increase the efﬁciency of cardiac regenerative therapies (Jain et al.,
2015). Another illustration is the recent demonstration that epicardial
cells feature a potent cardiogenic activity though the presence of
follistatin-like 1 (Fstl1). Application of the human Fstl1 protein
(FSTL1) via an epicardial patch stimulates cell cycle entry and division
of pre-existing cardiomyocytes, improving cardiac function and survival
in mouse and swine models of MI (Wei et al., 2015). Finally, exciting
new evidences suggest that a speciﬁc subtype of c-kit positive cells
such as the c-kit-positive/CD45 negative/tryptase negative cardiac
stem cells are necessary and sufﬁcient for myocyte regeneration, lead-
ing to complete cellular, anatomical, and functionalmyocardial recovery
(Ellison et al., 2013). These data have rationalized the use of right
atrium-derived c-kit+ progenitors in patients with both chronic left
ventricular dysfunction (Chugh et al., 2012) and recent myocardial in-
farction (CARE-MI trial, currently ongoing). Interestingly, the ability of
these cardiac progenitor cells to produce cardiomyocytes may depend
on speciﬁc signals from the cardiac milieu. A high-resolution genetic
lineage-tracing study in mice reveals that c-kit identiﬁes multipotent
progenitors of cardiac neural crest origin. The ability of these c-kit+-
progenitors to differentiate into cardiomyocytes is governed by the ac-
tivity of the bonemorphogenetic protein pathway, a signaling pathway
activated transiently during establishment of the cardiac crescent, and
extinguished from the heart before cardiac neural crest progenitor inva-
sion (Hatzistergos et al., 2015). Therefore, these ﬁndings likely resolve a
long-standing controversy concerning the in situ myogenic potential of
adult c-kit+ cardiac cells particularly in comparison to their neonatal
counterparts (Zaruba et al., 2010; Jesty et al., 2012) and suggest that
the homeostasis of the cardiac milieu regulates the cardiogenic poten-
tial of c-kit+ cardiac progenitor cells.
2. By the Way, How Does it Work?
To the best of our knowledge theworrisome answer to this question
is: we still don't know. By analogy, it is difﬁcult to picture any drug-
based approach for HF without a precise knowledge of its active princi-
ple and the type of receptor it is supposed to interact with. However, it
should be noted that despite the multiplicity of randomized clinical tri-
als in patients with HF the additional beneﬁt generated from the use of
novel drugs remains very modest, with the possible exception of therecently tested drug that combines blockade of angiotensin receptors
and neprilysin inhibition (Desai et al., 2015). We believe that one im-
portant reason for that stagnation is the focus on the optimization of
therapies that pursue already treated pathophysiological processes,
leading (at best) to incremental improvements in outcome. Hence, the
inherent advantage of stem cell therapy may be their ability to shape
non-redundant and critical disease-causing or aggravating pathways.
Nevertheless, a clear understanding of stem cell-based mechanisms of
action may lead to personalized medicine or, at least, to adaptation of
standard operating procedures to the type of HF patients (for example,
ischemic versus non-ischemic cardiomyopathy) and/or the stage of the
disease.
2.1. From Stem Cells to Biofactories
Initially, the objective of cell therapy was the integration of
transplanted cells within the recipient myocardium with the assump-
tion that their electrical coupling with host cardiomyocytes should
translate into a mechanical contribution of the cellular graft to contrac-
tile function. However, the ﬁrst generation of stem cell therapies used
adult stem cells with limited ability to differentiate into cardiomyocytes
even in vitro. As mentioned above, alternative sources of stem cells in-
cluding pluripotent stem cells have been considered to leverage their
intrinsic pluripotentiality and drive them towards a cardiac lineage.
However, even for iPSC-CMs for example, an increased differentiation
efﬁciency of cells derived from cardiac versus non-cardiac somatic
sources does not contribute to improved functional outcomes after MI
(Sanchez-Freire et al., 2014). In any case, it is then unlikely that a single
even highly competent and plastic pluripotent cell can at each crossroad
take the unique and correct decision required to become a cardiomyo-
cyte, especially in an ischaemic or failing heart (Puceat, 2013). Over
time, a major switch in the mechanistic archetype has occurred and
therapeutic cells are now increasingly thought to primarily act as reser-
voirs of a wide array of bioactive entities that trigger endogenous repair
pathways (Garbern and Lee, 2013) (Fig. 1). This statement is supported
by the sharp discrepancy between the scarcity of sustained cell engraft-
ment and themaintenance of a functional beneﬁt, therebymaking high-
ly unlikely that the low amounts of detectable cells can account for the
preservation of left ventricular function and geometry (Den Haan et al.,
2012; Riegler et al., 2015). Consistent with this, while intramyocardially
injected embryonic stem cell-derived cardiomyocytes have been shown
to couple with host cardiomyocytes, such was not the case when the
same cells were delivered under the form of an epicardial patch
(Gerbin et al., 2015). Nevertheless, several studies have shown that
cell-loaded patches with or without encapsulation were functionally
more effective than injected cells, thereby supporting the idea that
electro-mechanical integration is not a prerequisite for a successful out-
come (Bellamy et al., 2015; Levit et al., 2013).
Assuming that the grafted cells primarily act as biofactories, the ob-
vious question iswhether their phenotypemakes a difference, i.e., given
the fact thatmultiple cell types secretemultiple factors, one canwonder
whether cells could be easily exchangeablewith, ultimately, similar out-
come. However, as stated above, cardiac-committed cells display a
higher therapeutic efﬁcacy when compared to non-cardiac committed
stem cells (Rossini et al., 2011; Oskouei et al., 2012; Li et al., 2012;
Zheng et al., 2013; Citro et al. 2014). Furthermore, the better outcomes
associated with these cardiac-committed cells also manifest in terms of
paracrine factor production (Li et al., 2012) with a differential lineage-
speciﬁc expression of some cytokines which might impact on the ulti-
mate functional effects (Liu et al., 2014). In line with this reasoning,
human embryonic stem cell-derived cardiac progenitors show an un-
challenged ability to promote post-ischemic revascularization com-
pared with adult stem cells such as BM-derived mesenchymal stem
cells or cord-blood derived endothelial progenitor cells, despite a simi-
lar limited ability to incorporate into the targeted vascular network
(Richart et al., 2014).
Fig. 1. The evolution of the stem cell theory for heart failure. Initially, the objective of stem cell therapywas the integration of transplanted cells within the recipient myocardiumwith the
assumption that their electrical coupling with host cardiomyocytes should translate into a mechanical contribution of the cellular graft to contractile function. The majority of trials used
adult stem cells andmainly applied bonemarrow- aswell as peripheral blood-derivedmononuclear cells ormarker selected cells. Nevertheless, disregarded preclinical evidences suggest
that the best cardiac outcomes seem to be achieved by therapeutic cells of cardiomyocyte lineage. This leads to the development of cardiac-committed cell therapies using cardiosphere-
derived cells obtained from a right ventricular biopsy, c-kit-positive cardiac progenitor cells grown from an intra-operatively harvested right appendage biopsy and embryonic stem cell-
derived cardiac progenitors. However, the recent “big bang” in the evolution of the stem cell theory suggests that therapeutic cells rather act as reservoirs of a wide array of bioactive en-
tities that trigger multiple and synergic endogenous repair pathways. Abbreviations: BM: bone marrow, PB: peripheral blood; AT: adipose tissue; iPSCs: induced pluripotent stem cells;
ESCs: embryonic stem cells; SCs: stem cells.
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This paracrine mechanism involves multiple complementary and
likely non-exclusive pathways including stimulation of vascular growth
and remodeling; attenuation of ﬁbrosis; modulation of inﬂammation;
control of differentiated cell survival and recruitment/activation of
tissue-resident stem/progenitor cells. Altogether, these activated path-
ways are expected to synergistically improve tissue protection and pre-
serve cardiac function. The next question pertains to the nature of the
biomolecules released by transplanted cells.2.2.1. Therapeutic Cells and Cardiac Resident Cells
Stem cells from different origins have been shown to release angio-
genic and anti-apoptotic factors. In humans, bonemarrow-derived cells
secrete a cocktail of more than 25 factors and cytokines with
proangiogenic activities. These secreted molecules include angiogenin,
Vascular Endothelial Growth Factor (VEGF)-A, hepatocyte growth fac-
tor, and Fibroblast Growth Factor (FGF). Human and murine bone
marrow-derived mesenchymal stem cells also release a broad range of
factors with proangiogenic capacities including growth factors (VEGF,
FGF-2, FGF-7, insulin growth factor (IGF), platelet-derived growth fac-
tor, placenta growth factor metalloproteases (MMP-1, MMP-2, MMP-9, t-PA) and factors involved in stem/progenitor cells mobilization and
recruitment (Thymosine β4, SCF, G-CSF) (Gnecchi et al., 2005;
Haynesworth et al., 1996; Kinnaird et al., 2004a; Kinnaird et al.
2004b). Accordingly, bonemarrow-derived cells increase vascular den-
sity and local blood ﬂow through tissues (Kamihata et al., 2001; Tse
et al., 2007). The conditioned culture medium from cells of medullary
origin also protects cardiomyocytes against the cell death induced by is-
chemia/reperfusion (Korf-Klingebiel et al., 2008). IGF-1 produced by
mononuclear cells of medullary origin speciﬁcally inhibits the expres-
sion of the pre-microRNA (miR) and of the mature form of miRNA-
34a. This miRNA strongly induces the apoptosis of cardiomyocytes. In-
deed, the administration of mononuclear cells of medullary origin de-
creases the cardiac expression of miRNA-34a and cardiomyocyte
apoptosis, and improves the function of the infarcted heart. These ef-
fects are totally abolished by simultaneous treatment with an antibody
directed against IGF-1 (Iekushi et al., 2012). Similarly, transplantation of
human iPSC-CMs into an acute mouse MI model has been shown to im-
prove left ventricular function and attenuates cardiac remodeling, de-
spite limited engraftment. Microﬂuidic single-cell proﬁling of this
iPSC-derived cardiac progeny demonstrates that these cells release sig-
niﬁcant levels of proangiogenic and antiapoptotic factors in the ische-
mic microenvironment (Ong et al., 2015). However, if the vascular
compartment is the target, we should keep in mind that most of the
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cardiac tissue to promote vascular growth and remodeling (Silvestre
et al., 2013). In addition, a marked variability in the degree of collateral
development for a comparable severity of coronary artery obstructions
is a common clinical observation (Werner et al., 2000) and may there-
fore discriminate responder versus non-responder patients and partici-
pate to the heterogeneity in the results of clinical trials.
Stimulation of endogenous cardioblasts by exogenous cells can also
mediate the therapeutic regeneration of injured myocardium. This con-
cept was nicely explored in an elegant study in which cell therapy exper-
iments were carried out in mice constitutively producing the green
ﬂuorescent protein (GFP) exclusively in the cardiomyocytes following a
pulse of 4-OH-tamoxifen. The MI dilutes the pool of cardiomyocytes ex-
pressing GFP, revealing substitution with GFP-negative progenitors. The
administration of c-kit+ cells derived from bone marrow decreased fur-
ther the number of GFP+ cardiomyocytes. This effect was not associated
with transdifferentiation of c-kit+ cells into cardiomyocytes or with cell
fusion phenomena; it was associated with a stimulation of endogenous
cardiogenic progenitor activity (Loffredo et al., 2011). Similarly, cell ther-
apy with cardiosphere-derived cells ampliﬁes innate cardioblast-
mediated tissue regeneration, in part through the secretion of CXCL12
by transplanted cells. Genetically labeled isolated cardioblasts express
cardiac transcription factors and sarcomeric proteins, exhibit spontaneous
contractions, and formmature cardiomyocytes in vivo after injection into
unlabeled recipient hearts (Malliaras et al., 2014).
2.2.2. Therapeutic Cells and Cardiac Inﬁltrating Cells
Transplanted stem cells have also been shown to modulate the num-
ber and activation mode of inﬂammatory cells populating the cardiac tis-
sue. Bonemarrow-derived cells increase IL-1 and TNF-α in cardiac tissue,
three and seven days, respectively, after their administration (Kamihata
et al., 2001). Other cytokines have been identiﬁed among the many fac-
tors secreted by cells of medullary origin including the chemokines CCL-
2, CCL-23, CCL-24, CXCL-6, CXCL-12 and CXCL-13, as well as IL-10
(Haynesworth et al., 1996; Korf-Klingebiel et al., 2008). Furthermore,
the intramyocardial injection of IL-10 deﬁcient BM derived cells does
not rescue the defective cardiac function after MI. The IL-10-dependent
improvement provided by transplanted cells was not caused by reduced
infarct size, neutrophil inﬁltration, or capillary density, but rather was as-
sociated with decreased T lymphocyte accumulation, reactive hypertro-
phy, and myocardial collagen deposition (Burchﬁeld et al., 2008).
Cardiac homeostasis and inﬂammatory cells are intertwined and emerg-
ing evidences suggest that, notably, monocytes and/or macrophages
may provide the necessary signals to drive cardiogenesis. During the in-
ﬂammatory reaction, two sequential phases deﬁned by the expression
of Ly6C on monocytes can be identiﬁed in the infarcted myocardium
(Nahrendorf et al., 2007; Nahrendorf and Swirski, 2013). Many of these
monocytes may either die or exit the cardiac tissue whereas surviving
monocytes populating the ischemic milieu may acquire a macrophage
phenotype with M1-like and/or M2-like activation mode associated
with speciﬁc functions in the resolution of inﬂammation, tissue repair
and remodeling (Sica and Mantovani, 2012). Recent works also indicate
that the adult heart expands distinct populations of macrophages includ-
ing subsets of resident macrophages of embryonic origin, with opposite
roles in inﬂammation and cardiac recovery (Lavine et al., 2014;
Epelman et al., 2014a; Epelman et al., 2014b; Heidt et al., 2014). Interest-
ingly, using a cell-depletionmodel, it has been shown that heart regener-
ation and neoangiogenesis following MI depends on neonatal
macrophages. Neonates depleted of macrophages were unable to regen-
erate their cardiac tissue and formed ﬁbrotic scars, resulting in reduced
cardiac function. Immunophenotyping and gene expression proﬁling of
cardiac macrophages from regenerating and non-regenerating hearts in-
dicated that regenerative macrophages have a unique polarization phe-
notype and secrete numerous soluble factors that may facilitate the
formation of new myocardium (Aurora et al., 2014). Bone marrow-
derived cells (activated by LPS or TNF-alpha) reprogram macrophagesby releasing prostaglandin E(2) through activation of EP2 and EP4 recep-
tors and stimulation of IL-10 secretion (Nemeth et al., 2009). In keeping
with these observations, cardiosphere-derived cells reduced the number
of CD68+macrophages but polarized an effectormacrophage population
within the heart with distinctive cardioprotective phenotype. Conversely,
the systemic depletion of macrophages with clodronate abolished
cardiosphere-derived cells-mediated cardioprotection (De Couto et al.,
2015). Finally, IL-13 has been recently identiﬁed as a major regulator of
cardiomyocyte differentiation and proliferation as well as cardiac regen-
eration in the mouse model (O'meara et al., 2015). Whereas numerous
studies focus on innate immune cells, the role of the adaptive immune
system should also be considered especially since adaptive immunity
has been shown to regulate post-natal organogenesis and is known to
control cardiac remodeling after acute MI (Plaks et al., 2015; Zouggari
et al., 2013; Hofmann and Frantz, 2015).
This intrinsic cross talk between inﬂammatory cells and stem cells
may participate to the heterogeneity of the clinical results. First, the or-
igin and nature of stem cells may control their ability to modulate in-
ﬂammation and second the microenvironment of the cardiac target
tissue will certainly impact the inﬂammatory reaction. Hence, the time
of delivery or the type of HF patients likely dictates the overall effect
of therapeutic cells on the inﬂammatory response and subsequently
on cardiac function and remodeling.
However, regardless the mechanisms of action a precise characteri-
zation of the cell-released factors purportedly accounting for their ben-
eﬁts still remains elusive.
2.3. From Cell to Cell-Free Therapies
There is an increasing body of evidence that these factors could be
clustered in extracellular membrane vesicles. Extracellular membrane
vesicles (EVs), including exosomes and microparticles (MP) have been
detected in all biological ﬂuids and conditioned cell culture media and
appear to be secreted by all cell types. These vesicles are bounded by
lipid bilayer membranes and do not have nuclei. They contain mRNA,
miRNA, proteins, lipid rafts, and other bioactive molecules. They are
coated with surface markers, some of which are speciﬁc to the vesicle
sub-type. Exosomes and MP differ in their size and biogenesis;
exosomes are 30–150 μm in size and are formed within the late endo-
some,whileMP are 100–1000 μmand are shed from the cellmembrane.
These vesicles may contain key determinants necessary to maintain
stem cell properties and their quantitative reduction or loss may result
in cellular differentiation or phenotypic changes (Bauer et al., 2011). Al-
ternatively, they cargo a wide array of biomolecules, including
microRNAs, proteins, lipids and genetic material that they can transfer
to target cells to inﬂuence important differentiated cell functions and
even regulate other stem cells in their respective niches. Hence, MVs
from pluripotent embryonic stem cells are able to reprogram hemato-
poietic progenitors and revert them to a more primitive state
(Ratajczak et al., 2007). Their role asmediators of the effects of cell ther-
apy is demonstrated by their reparative effects in different disease states
(Leroyer et al., 2009) includingMI (Barile et al., 2014; Khan et al., 2015)
and by the observation that EV administration can largely recapitulate
the beneﬁts of transplanted cells. Interestingly, EVs-mediated transfer
of biomolecules to target cells occurs within a relatively short time
frame which would be consistent with the protective effects of
transplanted cells despite their fast clearance from the transplanted tis-
sue (Yuan et al., 2009). Consistent with this, bone marrow cell extracts
prepared by subjecting BM-derived cells to three freeze-thaw cycles
followed bymicrocentrifugation reduce infarct size and improve cardiac
function to a similar extends, as intact cells (Yeghiazarians et al., 2009).
Likewise, irradiated embryonic stem cells provide a signiﬁcant improve-
ment in cardiac function after MI (Burt et al., 2012) and, as mentioned
above, irradiation of embryonic stem cell-derived cardiomyocytes did
not prevent them to yield a functional outcome similar to that of their
viable counterparts (Riegler et al., 2015). So far, similar beneﬁcial roles
1876 J.-S. Silvestre, P. Menasché / EBioMedicine 2 (2015) 1871–1879have been attributed toMVs derived frommesenchymal stem cells (Lee
et al., 2012a), induced pluripotent stem cells (Bobis-Wozowicz et al.,
2015) and cardiosphere-derived cells (Tseliou et al., 2015) but the na-
ture of the optimal parent cell still remains to be deﬁned. Notably, EVs
contains a multitude of miRNAs, known to regulate endogenous repair
(Seeger et al., 2013), and some of them playing a pivotal role in tissue
protection induced by stem cell-derived EVs (Khan et al., 2015; Gray
et al., 2015). Nevertheless, the beneﬁcial effects of EVs likely rely on
the interplay of themultitude of factors that they cargo and it might ac-
tually be therapeutically counterproductive to deconstruct the vesicular
content. It is likely that because of the number of biologically active
compounds that they can release, these vesicles feature advantages
over the delivery of deﬁned factors that only target a single signaling
pathway.
Conﬁrmation that the use of EVs alone could successfully substitute
for cells would have major clinically relevant advantages with regard to
standard operating procedures, streamlining of the regulatory path and
ﬁnal costs. Nevertheless, speciﬁc attention should be paid to the pheno-
type and the mode of isolation/culture/puriﬁcation of the parent cells.
Genesis and release of EVs are indeed a very dynamic processes and
this may lead to heterogeneity in their biological activity and thus in
their therapeutic potential. Ultimately, the characterization of their
most active forms (i.e. exosomes versus MPs) and/or ingredients may
offer the perspective of possible synthesis of biomimetic compounds.
3. Conclusion
Lessons from cell-based therapies reveal that the next generation of
therapeutic approaches needs to better ﬁt the patient presentation and
the nature of the therapeutic product. First, amore systematic stratiﬁca-
tion of patients is required to delineate acute versus chronic disease, to
identify responders and non-responders and to take into account co-
morbidities to improve the response of the failing heart and better
shape future clinical trials. Second, emerging evidences suggest that
rather than transplanting cells that directly engraft and differentiate/
proliferate in the host tissue, delivering paracrine factors alone to the
damaged heartmay be sufﬁcient to activate repairmechanisms.Where-
as the initial autologous stem cell-based cardiac regeneration therapy
led to a rather rapid translation into early-phase clinical trials, the evo-
lution of the stem cell theory may ultimately lead to a more thoughtful
development of cell-free strategies with multiple targets including
cardiomyocytes but also other inﬁltrating or resident cardiac cells.
4. Outstanding Questions
The proﬁcient development of the next generation of stem cell-
based therapy for HFwill depend on the ability of the scientiﬁc commu-
nity to address threemajor existential questions. The ﬁrst question con-
cerns the cell type: the best outcomes seem to be achieved by
therapeutic cells phenocopying targeted cells into the affected territory.
This argues in favor of the use of cardiac-committed cells among which
the pluripotent stem cell-derived cardiac progeny is particularly attrac-
tive. However, the optimal stage at which these cells should be grafted
remains a critical but unsettled issue. Transplantation of mature, fully
differentiated ESC-derived cardiomyocytes has been shown functional-
ly effective to induce remuscularization of infarcted myocardium
(Chong et al., 2014) but, at the opposite, early progenitors feature the
possible advantages of a higher resistance to the hypoxic milieu they
are transplanted in and a greater plasticity in response to local cues
allowing the generation of both contractile and vascular cells, which,
in turn, might enhance graft survival. Since the use of pluripotent
stem cells now allows to tightly control the sequential steps of the car-
diac differentiation pathway, head-to-head comparisons of early pro-
genitors versus more mature cardiomyocytes are eagerly required to
deﬁne the optimal maturation level promoting both the highest en-
graftment and the most effective therapeutic effect. The secondquestion relates to themechanisms of action. The “big bang” in the evo-
lution of the stem cell theory leads to the unexpected assumption that
therapeutic cells primarily act as biofactories. This implies to focus on
early cell retention, rather than on sustained cell survival, allowing the
therapeutic cells to deliver sufﬁcient amounts of factors underpinning
their action. Biomaterials are here critical adjuncts to optimize this res-
idency time. The paracrine hypothesis also gives more ﬂexibility for
using allogeneic cells in that targeting an only transient engraftment re-
quires to delay, and no longer to avoid, rejection, thereby simplifying
immunomodulation regimens. The third question deals with
manufacturing since a broad dissemination of cardiac cell therapy re-
quires the development of automated systemswith highly reproducible
therapeutic products. The development of cell-free strategies may lead
to production process, similar to that of a pharmaceutical compound, fa-
cilitating an expended standardized clinical use. This also emphasizes
the interest of using allogeneic cells as a biosource for these therapeutic
paracrine factors (possibly clustered in extracellular vesicles) because of
their suitability for industrially-relevant and cost-effective scale-up and
quality control procedures. Regardless of the ﬁnal product to be used
(cells or their secretome), streamlining the production process is man-
datory to make this therapy cost-effective and allow to target the
large number of patients most likely to beneﬁt from it, i.e., those who
have exhausted conventional therapies of heart failure but have not
yet reached the end stage of their disease, inwhich case cardiac replace-
ment becomes the only option.
5. Search Strategy and Selection Criteria
Data from this review were identiﬁed by searches of PubMed and
references from relevant articles using the search terms “Heart failure”,
“Myocardial infarction”, “Stem cells”, “Bonemarrow”, “Cardiac regener-
ation”, “Paracrine”, “Inﬂammation”, “Exosomes”, and “Microparticles”.
Only articles published in English were included. Abstracts and reports
from meetings were excluded.
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